LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Aandelen Lijst・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Gesloten

11.12 -4.71

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

11.03

Max

11.24

Belangrijke statistieken
By Trading Economics
Inkomsten	-1.4M -14M
EPS	-0.15
Werknemers	37
EBITDA	-2.7M -15M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+184.17% upside

Dividenden
By Dow Jones
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-331M 1B
Vorige openingsprijs	15.83
Vorige sluitingsprijs	11.12

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 jun 2026, 19:20 UTC

Belangrijke Marktbewegers

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

5 jun 2026, 21:27 UTC

Winsten

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5 jun 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

5 jun 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

5 jun 2026, 20:20 UTC

Acquisities, Fusies, Overnames

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5 jun 2026, 20:19 UTC

Acquisities, Fusies, Overnames

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5 jun 2026, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

5 jun 2026, 19:26 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

5 jun 2026, 19:26 UTC

Marktinformatie

Hog Futures Tumble to Close Week -- Market Talk

5 jun 2026, 19:10 UTC

Marktinformatie

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5 jun 2026, 19:03 UTC

Marktinformatie

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5 jun 2026, 18:59 UTC

Marktinformatie

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5 jun 2026, 18:47 UTC

Marktinformatie

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5 jun 2026, 18:34 UTC

Marktinformatie

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5 jun 2026, 18:33 UTC

Acquisities, Fusies, Overnames

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5 jun 2026, 17:50 UTC

Winsten

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5 jun 2026, 17:27 UTC

Marktinformatie

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5 jun 2026, 16:48 UTC

Acquisities, Fusies, Overnames

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 jun 2026, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

5 jun 2026, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

5 jun 2026, 16:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

5 jun 2026, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

5 jun 2026, 15:44 UTC

Acquisities, Fusies, Overnames

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 jun 2026, 15:26 UTC

Marktinformatie

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5 jun 2026, 15:25 UTC

Winsten

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

5 jun 2026, 15:16 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

5 jun 2026, 15:16 UTC

Marktinformatie

Zcash Tumbles After Exploit Found -- Market Talk

5 jun 2026, 15:09 UTC

Marktinformatie

Canada's May Jobs Report Underscores Volatility Worries Over Data Collection -- Market Talk

5 jun 2026, 15:07 UTC

Marktinformatie

Canada's Economy Still Has Legs With Total Employment Close to Record -- Market Talk

5 jun 2026, 15:05 UTC

Marktinformatie

Canada's Labor-Market Weakness to Start 2026 Likely 'Overstated' -- Market Talk

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

184.17% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 31.6 USD 184.17%

Hoogste 40 USD

Laagste 27 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Corvus Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.